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OBJECTIVE—This study investigated the relationship between circulating soluble receptor
for advanced glycation end products (sRAGE) and parameters of bone health in patients with
Charcot neuroarthropathy (CNA).
RESEARCHDESIGNANDMETHODS—Eightymen(aged55.3 69.0years),including
30 healthy control subjects, 30 type 2 diabetic patients without Charcot, and 20 type 2 diabetic
patients with stage 2 (nonacute) CNA, underwent evaluations of peripheral and autonomic
neuropathy, nerve conduction, markers of bone turnover, bone mineral density, and bone
stiffness of the calcaneus.
RESULTS—CNA patients had worse peripheral and autonomic neuropathy and a lower bone
stiffness index than diabetic or control individuals (77.1, 103.3, and 105.1, respectively; P ,
0.05),butno differenceinbonemineraldensity(P.0.05).CNAsubjectsalsohadlowersRAGE
levels than control (162 vs. 1,140 pg/mL; P , 0.01) and diabetic (162 vs. 522 pg/mL; P , 0.05)
subjects, and higher circulating osteocalcin levels.
CONCLUSIONS—CNA patients had signiﬁcantly lower circulating sRAGE, with an ac-
companying increase in serum markers of bone turnover, and reduced bone stiffness in the
calcaneusnotaccompaniedbyreductionsinbonemineraldensity.Thesedatasuggestafailure
of RAGE defense mechanisms against oxidative stress in diabetes. Future studies should de-
termine if medications that increase sRAGE activity could be useful in mitigating progression
to CNA.
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C
harcot neuroarthropathy (CNA) is
a progressive, degenerative process
that usually occurs in the ankle and
midfoot. Although not exclusive to pa-
tients with diabetes, this condition will
develop in ;1 in 600 patients with dia-
betes and 1 in 100 with neuropathy,
although no current large-scale epidemio-
logic study has reported the true incidence
of CNA (1,2). Clinical manifestations are
marked by tissue and bone inﬂammation,
bone destruction, resorption, and eventual
joint deformity.
CNA is likely caused by a complex
interaction between predisposing fac-
tors, including the presence of diabetes,
neuropathy, and an intact peripheral cir-
culation that provides the ability to
mount an inﬂammatory response (3).
The “neurovascular theory” of CNA, pro-
posed by Charcot in 1868, suggests that
bony changes result from damage to
the central nervous system that directly
controls bone nutrition and leads to
uncontrolled inﬂammation. The “neuro-
traumatictheory”proposedshortlythere-
after, however, postulates that CNA may
betriggeredbyexternaltraumatothefoot
that sets the inﬂammatory response in
motion. In either case, the progression
of inﬂammation eventually leads to bone
lysis, microfracture, and bone deformity.
The work of Mabilleau and Edmonds (4)
suggests both theories have merit, and
that although osteoclastic resorption me-
diated by receptor activator for nuclear
factor-kB ligand (RANKL)occurs inacute
Charcot osteoarthropathy, a RANKL-
independent pathway mediated by pro-
inﬂammatory cytokines may also be
important (5).
The formation of advanced glycation
end products (AGEs), driven by hyper-
glycemia and oxidative stress, is an im-
portant biochemical abnormality that
accompanies diabetes and inﬂammation
in general. An increase in AGE-modiﬁed
collagen has been detected in tissues with
the slowest turnover, such as the cortical
bone of diabetic and old rats (6). This
modiﬁed collagen may play a role in the
pathogenesis of osteopenia present in pa-
tients whose diabetes is poorly controlled
(7). AGEs also stimulate apoptosis of hu-
man mesenchymal stem cells (8) and os-
teoblast apoptosis through a nuclear
factor-kB–independent mechanism that
further limits bone formation (9). A pro-
posed mechanism through which diabe-
tes induces apoptosis by stimulating
AGEs is via N-(carboxymethyl)lysine col-
lagen, mediated through receptor for ad-
vanced glycation end products (RAGE),
the pattern recognition receptor for
AGE. RAGE is constitutively expressed
but is induced by reactions known to ini-
tiate inﬂammation. RAGE has been sug-
gested to increase the activation of
RANKL, leading to enhanced osteoclasto-
genesis and impaired matrix mineraliza-
tion (10,11).
We have previously shown an in-
crease in skin blood ﬂow in the affected
foot of Charcot patients (12). In addition,
wehavesuggestedderangementsinChar-
cot collagen structure of the Achilles’ ten-
don, perhaps caused by accumulation of
AGE cross-links (13,14), and a reduction
in calcaneal bone stiffness despite normal
foot bone mineral density (BMD) values
in Charcot patients (15). These ﬁndings
correlate CNA pathogenesis with bone
quality, rather than bone density, which
m a yb eam o r ei m p o r t a n tp r e d i c t o ro f
fracture than bone density alone (11).
Our previous observations and the
suggestion by others that RAGE-enhanced
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Pathophysiology/Complications
ORIGINAL ARTICLEosteoclastogenesis impairs matrix miner-
alization led us to investigate the rela-
tionship between circulating sRAGE and
parameters of bone health in patients
with CNA. We hypothesized that CNA
patients would display more severe neu-
ropathy,worse bone health, and decreased
sRAGEthandiabeticpatientswithoutCNA
or healthy control individuals.
RESEARCH DESIGN AND
METHODS—For this cross-sectional
study, we recruited men with type 2 di-
abetes (with and without CNA), and at-
tempted to age-match them with healthy
control subjects. Inclusion criteria for the
diabetic participants (with and without
CNA) included ambulatory men aged
between 40 and 80 years with established
type 2 diabetes for more than 5 years and
diabetes-derived nervedamage.Exclusion
criteria included a documented history
of vitamin D deﬁciency, thyroid disease,
renal disease, or other metabolic diseases
known to affect bone, as well as prior oral
or intravenous antiresorptive drug use.
Charcot patients had to be ambulatory
and in the nonacute, convalescence stage
(stage 2) of the disease, which is different
from acute stage (stage 1) that is charac-
terized by osseous resorption, soft-tissue
swelling, and joint effusions (16). Control
subjects were healthy, with no known
chronic disease. This study was approved
by the Eastern Virginia MedicalSchool In-
stitutional Review Board, and all subjects
provided written consent before partici-
pating in this study.
The inclusion criteria for the study
w e r em e tb y8 0m e n ,c o m p r i s i n g3 0
healthy control subjects, 30 type 2 di-
abetic patients without Charcot, and 20
type 2 diabetic patients with stage 2 CNA.
Many of the CNA patients had, however,
already undergone stabilization of the
fractured or dislocated joints with beam-
ing screws and other means of metallic
ﬁxation. Descriptive characteristics for all
subjects are reported in Table 1. Subjects’
evaluation consisted of an analysis of fast-
ing blood chemistries; a complete neuro-
logic examination, including quantitative
sensory, autonomic nerve function, and
nerve conduction tests; a bone density as-
sessment; and quantitative ultrasound im-
aging of bilateral calcanei.
Nerve conduction studies
Lower limb nerve conduction parameters
were measured bilaterally by surface
stimulationofthe sural,peroneal, andtibial
nerves. Measurements included peroneal
and tibial motor nerve amplitude, con-
duction velocity, distal onset latency, and
F wave. All motor amplitudes were mea-
sured baseline to peak, and latencies were
taken as onset latency. Motor conduction
velocity was calculated as total conduc-
tion velocity (not segmental) using onset
latencies throughout. Sensory amplitude
was taken as baseline to peak, latency
was reported as onset latency, and con-
duction velocity was calculated across
the single segment using onset latency
(Neuromax, Excel-Tech Ltd., Oakville,
ON, Canada).
Quantitative sensory tests
Quantitative sensory testing was per-
formedusingtheMedocdeviceaccording
to previously published methods (17).
Warm and cold thermal thresholds and
heat and cold pain were tested using the
TSA2001/VSA3001 computer-driven
sensorymeasuringdevice(Medoc,Durham,
NC).Touchpressurewasmeasuredusing
graded Semmes-Weinstein monoﬁlaments
(18). Vibration perception threshold was
quantiﬁed using the Medoc device and
the “method of limits” protocol, where re-
peated, increasing vibratory stimulation is
applied to the plantar aspect of the domi-
nant great toe. Subjects pushed a hand-held
button as soon as they detected the
vibration. The mean result of six trials was
used in all analyses.
Autonomic function tests
Autonomic function was assessed by
three tests using the ANX-3.0 Autonomic
Monitor: heart rate variability during deep
breathing at six breaths per min (E/I ratio)
a n dR / Rv a r i a t i o ni nr e s p o n s et ot h e
Valsalva maneuver and postural change
(ANSAR Medical Technologies, Inc.,
Philadelphia, PA) (19).
BMD
BMD scans of the whole body, bilateral
proximal femurs, and bilateral feet were
obtainedusing dual-energyX-rayabsorp-
tiometry (GE Lunar Prodigy Advance, GE
Healthcare, Waukesha, WI). Scans were
performed according to the manufac-
turer’s protocols, with the exception of
the feet, for which no standardized pro-
tocol exists. Therefore, we developed a
technique that used the “hand” mode,
where a subject sat on the edge of the
scan bed with the knee bent at 90º and
thefootﬂatonthebed.Thelasermarker
was positioned at the midline of the an-
kle, at the level of the lateral malleolus.
During analysis, the region of interest
was selected manually and included
Table 1—Patient demographics
Variable
Control subjects
(n =3 0 )
Diabetic subjects
(n =3 0 )
Charcot subjects
(n = 20)
Duration of diabetes
(months) — 133 6 80 178 6 100
Age (years) 52.9 6 7.7 (40–69) 57.8 6 8.8* (41–73) 57.9 6 10.1* (43–78)
Race
Black 10 15 3
White 19 15 16
Asian 1 0 0
Hispanic 0 0 1
Weight (kg) 89.4 6 15.2 99.9 6 18.8* 110.0 6 23.4*
BMI (kg/m
2) 28.8 6 6.2 32.9 6 7.0* 33.7 6 5.6*
Waist-to-hip ratio 0.94 6 0.06 1.01 6 0.05* 1.02 6 0.06*
BP (mmHg)
Systolic 132 6 13.8 137.9 6 14.4 149.7 6 19.7*
Diastolic 82.3 6 10.5 82.6 6 12.5 83.1 6 7.4
HbA1c (%) 6.1 6 1.0 7.0 6 2.9 8.3 6 1.6*
Glucose (mg/dL) 84.6 6 26.1 147.0 6 77.0* 171.4 6 107.9*
Total calcium (mg/dL) 8.9 6 0.6 8.9 6 0.6 8.8 6 0.6
Parathyroid hormone
intact (pg/mL) 32.5 6 24.1 18.1 6 15.4† 38.3 6 19.7
Vitamin D 25OH (ng/mL) 19.4 6 9.7 16.4 6 8.1 17.9 6 9.6
Continuousdataareexpressedas mean6SD (range), andcategoricdataasn. *P,0.05 vs.controlsubjects.
†P , 0.05 vs. control and Charcot subjects.
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Loss of RAGE defense in CNAonly the metatarsals and phalanges to
exclude any metal ﬁxators.
Test-retest reliability for this measure
is high (r = 0.96, n = 31), and the coefﬁ-
cient of variation is ,1% for our labora-
tory. This corresponds well to other
published studies of reproducibility of
BMD using the hand mode (20), and is
also comparable with other regional anal-
yses of bone, where coefﬁcients of varia-
tion typically range from 0.5 to 1.2%.
Because no reference database currently
exists for scans of the feet, diabetic pa-
tients were compared with sex- and age-
matched control subjects.
Calcaneal stiffness
Calcaneal stiffness was determined using
quantitative ultrasound imaging (GE
Achilles Express, Waukesha, WI). Bone
stiffness is automatically computed using
an algorithm supplied by the manufac-
turer: stiffness index = 0.67 3 BUA 6
0.28 3 SOS 2 420, where BUA is broad-
band ultrasound attenuation and SOS is
the speed of sound through the tissues
(GE Healthcare). Because bone stiffness
predicts fracture independent of BMD, it
is considered to be a measure of bone
quality that also accounts for factors re-
lated to fracture that might not be detected
by a measure of BMD alone.
Blood measures
Fasting blood samples were obtained by
antecubital venipuncture into serum sep-
arator tubes and separated immediately
by refrigerated centrifugation. The serum
wasstoredat280°Caccordingtoinstruc-
tionsrequiredbythemanufacturersofthe
enzyme-linked immunosorbent assay
(ELISA) kit. Samples were subsequently
evaluated in duplicate for sRAGE by the
Quantikine RAGE enzyme-linked immu-
noassay(R&DSystems,Minneapolis,MN);
cross-linked N-telopeptides of type 1
(NTx) collagen, as a measure of bone re-
sorption (Osteomark NTx ELISA/EIA,
Wampole Laboratories, Princeton, NJ);
and osteocalcin, as a measure of bone for-
mation (ALPCO Diagnostics, Salem, NH).
Statistical analysis
Group differences on each dependent
measure were evaluated using one-way
ANOVA with a least signiﬁcant differ-
ences post hoc analysis. Pearson-product
momentcorrelationswerealsoperformed
to determine signiﬁcant relationships
among variables. A multiple linear step-
wise regression analysis was run to help
identifyfactorsthatmaydistinguishthose
who develop CNA from those who do
not.AllanalyseswererunusingSPSS18.0
software (SPSS Inc., Chicago, IL) with
signiﬁcance set at P , 0.05.
RESULTS—We evaluated 80 adult
men, aged 55.3 6 9.0 years, consisting
of 30 healthy control subjects, 30 type 2
diabetic patients, and 20 type 2 diabetic
patients diagnosed with stage 2 CNA. Ac-
cording to the classiﬁcation scheme of
Sanders and Frykberg (16) to describe
neuropathic osteoarthropathy patterns
of joint involvement, 28% of CNA pa-
tients displayed pattern 2 (tarsometatarsal/
Lisfranc’s joint involvement), 45% dis-
played pattern 3 (midtarsal and naviculo-
cuneiform joint involvement), and 27%
displayed pattern 4 (ankle and subtalar
joint involvement). No patients were clas-
siﬁed as pattern 1 (forefoot) or pattern 5
(calcaneus), which might have otherwise
interfered with the measurement of BMD
or calcaneal stiffness, or both.
CNA patients had similar duration of
diabetes but higher HbA1c levels than
their counterparts with diabetes (8.3 6
1.6 vs. 7.0 6 2.9%, Table 1). Fasting se-
rum blood urea nitrogen and creatinine
values for all diabetic and CNA patients
were within the normal reference ranges.
CNA and diabetic patients were slightly
older, had a greater BMI, and a higher
waist-to-hip ratio than control subjects.
Systolic blood pressure was higher in
CNA subjects than in diabetic or control
participants.
Diabetic and CNA patients showed
more peripheral nerve damage than con-
trol subjects, and CNA subjects exhibited
the highest degree of sympathetic and
parasympathetic dysfunction and small
and large ﬁber neuropathy compared with
the other study groups (Table 2).
BMD of the proximal femur was
slightly higher at the femoral neck and
greater trochanter for diabetic patients
than for CNA or control individuals, but
BMD of the feet was not signiﬁcantly
different across groups (Table 3). Calca-
neal stiffness was similar for diabetic and
control subjects but was markedly re-
duced in the CNA patients (P , 0.01).
These results indicate that ultrasound im-
aging may detect features that are not de-
tectable by BMD scans using dual-energy
X-ray absorptiometry.
Osteocalcin was only elevated in
CNA, and NTx did not differ across
groups. CNA patients displayed sRAGE
values more than seven times lower than
control subjects and more than three
times lower than diabetic patients (P ,
0.05). Across all subjects, there was a sig-
niﬁcant positive correlation between the
calcaneal bone stiffness index and sRAGE
Table 2—Peripheral and autonomic neuropathy tests
Control subjects Diabetic subjects Charcot subjects
Variable n =3 0 n =3 0 n =2 0
Tibia-ankle
Amplitude (mV) 8.9 6 4.1 4.3 6 3.8* 0.6 6 1.0†
Latency (msec) 4.7 6 0.7 4.2 6 1.8 3.6 6 5.5
Conduction velocity (m/sec) 45.4 6 3.7 35.4 6 15.2* 7.7 6 13.1†
F-wave (msec) 54.7 6 6.4 47.5 6 23.3 17.5 6 29.7†
Peroneal-ankle
Amplitude (mV) 4.8 6 2.2 2.6 6 2.3* 0.1 6 0.3†
Latency (msec) 14.1 6 2.1 13.6 6 5.2 8.9 6 9.4†
Conduction velocity (m/sec) 44.5 6 3.3 35.6 6 13.1* 16.4 6 17.0†
F-wave (msec) 42.2 6 22.1 38.8 6 27.2 4.3 6 17.2†
Positive sural response 30 28 4
Vibration perception (m) 10.6 6 11.1 31.7 6 27.3* 100.5 6 31.5†
Pressure perception (g) 2.9 6 0.4 3.1 6 0.3 5.9 6 1.2†
Cold sensation (°C) 5.5 6 2.7 7.7 6 5.2 20.9 6 9.9†
Warm sensation (°C) 7.1 6 3.1 10.3 6 3.2* 14.9 6 3.2†
Cold pain 24.5 6 9.0 26.4 6 6.6 30.6 6 3.5†
Warm pain 14.0 6 3.3 15.4 6 2.5* 17.5 6 1.0†
Valsalva ratio 1.43 6 0.25 1.36 6 0.31 1.18 6 0.28†
Parasympathetic deep breathing 611 6 13 617 6 13 632 6 18†
Sympathetic Valsalva response 714 6 17 713 6 16 717 6 20
Continuous data are expressed as mean 6 SD; categoric data as n. *P , 0.05 vs. control subjects. †P , 0.05
vs. diabetic and control subjects.
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Witzke and Associates(r = 0.35, P , 0.01) and a negative corre-
lation between stiffness index and osteo-
calcin (r = 20.39, P , 0.001). These
results demonstrate across-sectionalrela-
t i o n s h i pb e t w e e na ni m p a i r e dA G Ed e -
fense, increased bone turnover, and
reduced bone stiffness.
In multiple linear stepwise regression
analysis, when measures of large and
small ﬁber neuropathy, autonomic neu-
ropathy, blood measures, BMD,andbone
stiffness were entered into the model,
74.5%ofgroupmembershipwaspredicted
by vibration perception, pressure percep-
tion, and sRAGE (r
2 =0 . 7 4 5 ,P , 0.001).
Similarly,vibration perception and sympa-
thetic Valsalva response accounted for
50.3% of the variability in bone stiffness
(r
2 =0 . 5 0 3 ,P , 0.001), indicating a pos-
sible relationship of both large ﬁber and
autonomicneuropathiesintheprogression
to CNA.
CONCLUSIONS—The two most im-
portant ﬁndings from this study were
1) an indication that Charcot patients
have an impaired RAGE defense mecha-
nism with an accompanying increase in
serum markers of bone turnover, and 2)
reduced bone stiffness in the calcaneus,
not accompanied by reductions in bone
mineral density.
In this study, sRAGE values in CNA
patients were reduced by 86%, but the
diabetic patients had a 50% reduction
compared with control subjects. Hyper-
glycemia generates higher levels of AGE,
but without adequate sRAGE to bind
AGE, it and other ligands tend to accu-
mulateintissueswithslowturnover,such
as tendon, skin, bone, amyloid plaques,
and cartilage (21). Accumulation of AGE
has been shown to reduce osteoblastic
activity via an increase in RAGE that
increases RANKL activation that leads to
enhanced osteoclastogenesis and im-
paired matrix mineralization (10,11,22).
Thiscascadepredisposesbonetofracture.
Although our biomarker for bone resorp-
tion (NTx) was not different between
groups, this does not preclude the possi-
bilitythat bone maybeinadequatelymin-
eralized and not contributing to bone
strength. Studies have demonstrated
that bone toughness and stiffness are af-
fected by AGE cross-link formation, and
the elastic modulus is independent of
other determinants of bone strength
such as bone density and microarchitec-
ture (23,24). Our ﬁnding that bone stiff-
ness detected by quantitative ultrasound
imagingwasmarkedlylowerinCNAsub-
jects, despite BMD values in the feet and
proximal femur within normal reference
ranges, supports the notion that bone
stiffness is not necessarily correlated
with BMD in certain disease states.
Osteocalcin, a marker of bone forma-
tion, was only elevated in CNA subjects.
Elevated bone formation activity in Char-
cot patients is likely the result of an
accumulation of microfractures, and an
excessive attempt at bone repair to main-
tain bone integrity of the foot. So taken
together, our ﬁnding that CNA patients
display higher levels of bone formation
markers and reduced sRAGE may suggest
thatCNApatientsaresusceptibletoAGE-
mediated osteoblast apoptosis, thereby
limiting their ability to repair bone. This
representsanotherpossiblepathwaylink-
ingCNAtobonelossbesidestheRANKL/
osteoprotegerin pathway. It would be
valuabletoinvestigatewhethercertaindrugs
that raise RAGE levels (e.g., ACE inhibitors,
statins,andglitazones)(25),mayalsohavea
role in the prevention of Charcot progres-
sion in patients with severe neuropathy.
We have shown, along with others,
that Charcot patients display signiﬁ-
cantly worse autonomic neuropathy
(both sympathetic and parasympathetic)
thandiabeticorcontrolsubjects.Thisisan
important ﬁnding, because it has recently
been suggested that the presence of CNA
may coincide with a loss of sympathetic
activity that allows shunt vessels to open,
which increases perfusion of the feet and
may speed bone resorption (12). Simple
autonomic function tests may indeed be
useful tools to detect an increased predis-
position to developing CNA in those with
diabetes.
A limitation of our study was the
slightly older age of the diabetic and CNA
patients compared with control subjects,
despite an attempt to age-match subjects.
Although BMD is age-dependent, BMD
did not differ between the groups. In
addition, bone stiffness and RAGE levels
were still different between diabetic and
CNA individuals, despite the presence of
diabetes for a similar duration. Therefore,
we were not concerned that these com-
parisons were confounded by the 5-year
difference in average age between the
diabetic and CNA subjects and the con-
trol group. Although all of our CNA
patients were in the chronic stage 2 of
the disease, we did include patients who
had recently undergone operative stabili-
zation. This type of stabilization, how-
ever, does not represent a “cure” or even
improvement of the underlying disease
process.Itispossible,however,thatpost-
surgical CNA patients may possess a
different biochemical proﬁle than pre-
surgical patients. None of our CNA pa-
tients had involvement of the calcaneus
ormetatarsals,sowewereconﬁdentthat
our measures of bone stiffness and BMD
were accurate. Lastly, we did not evalu-
ate classic inﬂammation or oxidative
stress markers, which would have added
signiﬁcantly to the argument that reduc-
tions in sRAGE promote inﬂammation or
oxidative stress, or both.
In summary, we show that there is a
spectrum of sRAGE deﬁciency wherein
diabetes reduces sRAGE levels by 50%,
suggesting a role in the complications of
diabetes. Furthermore, CNA patients
who have progressed to stage 2 have an
86% reduction in sRAGE and extremely
advanced somatic and autonomic neu-
ropathy that may prevent a normal de-
fense against oxidative stress and may
predispose them to reductions in bone
integrity and strength. To further eluci-
date the deleterious effects of CNA on
Table 3—Blood biomarkers, bone density, and stiffness
Control subjects Diabetic subjects Charcot subjects
Variable n =3 0 n =3 0 n =2 0
NTx (nmol/L) 13.6 6 5.5 11.4 6 5.7 13.8 6 8.2
Osteocalcin (ng/mL) 1.29 6 0.96 1.23 6 0.68 2.29 6 2.57*
sRAGE (pg/mL) 1140 6 471 522 6 660† 162 6 67*
BMD (g/cm
2)
Femoral neck 1.004 6 0.141 1.048 6 0.184‡ 0.904 6 0.219
Greater trochanter 1.080 6 0.157 1.116 6 0.165‡ 0.987 6 0.185
Total hip 1.018 6 0.129 1.037 6 0.150 0.955 6 0.252
Foot 0.754 6 0.081 0.792 6 0.105 0.788 6 0.120
Calcaneal stiffness index 105.2 6 14.0 103.3 6 18.6 77.1 6 26.2*
Dataarepresentedasmean6SD.*P,0.05vs.diabeticandcontrolsubjects.†P,0.05vs.controlsubjects.
‡P , 0.05 vs. Charcot subjects.
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Loss of RAGE defense in CNAcollagen and bone quality, future studies
could evaluate components of bone qual-
ity such as bone microarchitecture and
mineralization from calcaneal biopsy
specimens of CNA patients. In addition,
it would be very valuable to fully explore
the protective potential of medications
that elevate RAGE on bone formation
pathways in this vulnerable population.
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